Sarepta Therapeutics Inc. (SRPT)
62.33
0.42 (0.68%)
At close: Apr 02, 2025, 3:59 PM
57.33
-8.02%
After-hours: Apr 02, 2025, 05:28 PM EDT
Sarepta Therapeutics Inc. Revenue Breakdown
| Quarter | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|
| A M O N D Y S Fourty Five Revenue | 26.66M | 6.94M | 193K |
| A M O N D Y S Fourty Five Revenue Growth | +284.30% | +3493.78% | n/a |
| E X O N D Y S Fifty One Revenue | 115.6M | 112.46M | 107.19M |
| E X O N D Y S Fifty One Revenue Growth | +2.79% | +4.92% | n/a |
| V Y O N D Y S Fifty Three Revenue | 24.66M | 22.44M | 17.55M |
| V Y O N D Y S Fifty Three Revenue Growth | +9.87% | +27.89% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| United States Revenue | 797.94M | 747.1M |
| United States Revenue Growth | +6.81% | n/a |
| Rest Of World Revenue | 146.58M | n/a |
| Rest Of World Revenue Growth | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 128.2M | 136.66M | 127M | 131.7M | 120.89M | 118.56M | 110.71M | 120.48M | 104.79M | 154.32M | 71.84M | 78.06M | 61.13M | 72.35M | 71.13M | 86.05M | 75.37M | 73.69M | 82.77M | 81.42M | 75.43M | 67.39M | 60.57M | 64.22M | 53.04M | 49.38M | 43.34M | 32.22M | 28.18M | 36.07M | 26.22M | 22.94M | 22.18M | 17.75M | 20.88M | 24.33M | 15.09M | 12.93M | 22.7M |
| Selling, General, and Administrative Revenue Growth | -6.19% | +7.60% | -3.57% | +8.94% | +1.96% | +7.09% | -8.10% | +14.97% | -32.10% | +114.81% | -7.96% | +27.69% | -15.51% | +1.71% | -17.33% | +14.16% | +2.29% | -10.97% | +1.65% | +7.95% | +11.92% | +11.27% | -5.69% | +21.07% | +7.42% | +13.93% | +34.51% | +14.36% | -21.88% | +37.58% | +14.30% | +3.39% | +24.97% | -14.96% | -14.19% | +61.23% | +16.73% | -43.05% | n/a |
| Research and Development Revenue | 224.48M | 173.71M | 194.35M | 195.52M | 194.3M | 241.89M | 245.68M | 213.8M | 216.71M | 252.33M | 194.25M | 197.3M | 139.12M | 239.62M | 195.15M | 207.24M | 190.44M | 188.52M | 136.14M | 223.14M | 133.95M | 113.27M | 90.55M | 146.21M | 86.58M | 122.85M | 46.2M | 44.44M | 34.24M | 58.91M | 29.12M | 70.75M | 34.35M | 44.35M | 38.83M | 41.38M | 36.67M | 29.18M | 39.16M |
| Research and Development Revenue Growth | +29.23% | -10.62% | -0.60% | +0.63% | -19.67% | -1.54% | +14.91% | -1.34% | -14.12% | +29.90% | -1.54% | +41.82% | -41.94% | +22.79% | -5.83% | +8.82% | +1.02% | +38.47% | -38.99% | +66.59% | +18.26% | +25.08% | -38.07% | +68.86% | -29.52% | +165.88% | +3.97% | +29.80% | -41.88% | +102.30% | -58.84% | +105.97% | -22.55% | +14.22% | -6.16% | +12.82% | +25.68% | -25.49% | n/a |